Relmada Therapeutics (RLMD) Accounts Payables (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Accounts Payables data on file, last reported at $5.7 million in Q1 2026.

• On a quarterly basis, Accounts Payables rose 353.07% year-over-year to $5.7 million in Q1 2026; TTM through Mar 2026 was $5.7 million, a 353.07% increase from a year earlier, with the FY2025 full-year figure at $1.6 million, down 62.02% from the prior year.
• Accounts Payables for Q1 2026 stood at $5.7 million, up from $1.6 million in the prior quarter.
• Over the last five years, Accounts Payables for RLMD reached as high as $10.7 million in Q1 2022 and fell as low as $1.3 million in Q1 2025.
• Historically, Accounts Payables has averaged $4.5 million across 5 years, with a median of $4.2 million in 2024.
• Across the five-year window, Accounts Payables sank 75.62% in 2025 and surged 353.07% in 2026, its largest moves.
• Year by year, Accounts Payables stood at $5.3 million in 2022, then slumped by 33.37% to $3.5 million in 2023, then grew by 17.81% to $4.1 million in 2024, then plunged by 62.02% to $1.6 million in 2025, then surged by 265.3% to $5.7 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $5.7 million in Q1 2026, $1.6 million in Q4 2025, and $1.5 million in Q3 2025.